{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:22:01Z","timestamp":1792725721773,"version":"4.5.0"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Immune checkpoint inhibitor-induced diabetes is a potentially severe and life-threatening complication of immune checkpoint inhibitor therapy in patients with advanced malignancies. It is typically an irreversible complication due to the complete destruction of pancreatic beta cells that requires ongoing insulin treatment, and patients often exhibit labile diabetes. Inflammatory cytokines, including TNF-\u03b1, are thought to play a role in the development of this form of diabetes, as they do in spontaneous autoimmune diabetes. TNF-\u03b1 has also been implicated in the development of other immune-related adverse events caused by immunotherapy, and infliximab, a TNF-\u03b1 monoclonal antibody, has shown efficacy in several of these complications. We tested whether infliximab could preserve beta-cell function in immune checkpoint inhibitor-induced diabetes. We present two cases in which infliximab treatment appeared to halt beta-cell destruction, as evidenced by maintenance of C-peptide levels, as well as improved clinical outcomes in terms of diabetes control.<\/jats:p>","DOI":"10.3389\/fendo.2025.1697724","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:21:18Z","timestamp":1762492878000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Immune checkpoint inhibitor-induced diabetes can potentially be effectively treated with infliximab: a case report of two patients"],"prefix":"10.3389","volume":"16","author":[{"given":"Noam","family":"Savion Gaiger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Hurwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Hafez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet M.","family":"Kluger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevan C.","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Luisa","family":"Perdigoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-050219-034237","article-title":"Autoimmune endocrinopathies: an emerging complication of immune checkpoint inhibitors","volume":"72","author":"Quandt","year":"2021","journal-title":"Annu Rev Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/jamaoncol.2017.2391","article-title":"Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma","volume":"4","author":"Shoushtari","year":"2018","journal-title":"JAMA Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09618-w","article-title":"Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature","volume":"22","author":"Lo","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-2202","article-title":"Risk factors and characteristics of checkpoint inhibitor-associated autoimmune diabetes mellitus (CIADM): A systematic review and delineation from type 1 diabetes","volume":"46","author":"Wu","year":"2023","journal-title":"Diabetes Care"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e156330","DOI":"10.1172\/jci.insight.156330","article-title":"Immune cells and their inflammatory mediators modify \u03b2 cells and cause checkpoint inhibitor-induced diabetes","volume":"7","author":"Perdigoto","year":"2022","journal-title":"JCI Insight"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0054","article-title":"Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study","volume":"32","author":"Mastrandrea","year":"2009","journal-title":"Diabetes Care"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2006136","article-title":"Golimumab and beta-cell function in youth with new-onset type 1 diabetes","volume":"383","author":"Quattrin","year":"2020","journal-title":"New Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00584-4","article-title":"TNF in the era of immune checkpoint inhibitors: friend or foe","volume":"17","author":"Chen","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0469-9","article-title":"Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis (vol 6, 103, 2018)","volume":"7","author":"Johnson","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0908","article-title":"Successful treatment of immune checkpoint inhibitor-induced diabetes with infliximab","volume":"42","author":"Trinh","year":"2019","journal-title":"Diabetes Care"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0567","article-title":"Clinical impact of residual C-peptide secretion in type 1 diabetes on glycemia and microvascular complications","volume":"44","author":"Jeyam","year":"2021","journal-title":"Diabetes Care"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1697724\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:21:19Z","timestamp":1762492879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1697724\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":12,"alternative-id":["10.3389\/fendo.2025.1697724"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1697724","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"article-number":"1697724"}}